5 unchanged sentences
Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
−Removed: None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.
+Added: The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”) or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
+Added: Action Taken (Date of Action)
+Added: Type of Trading Arrangement
+Added: Nature of Trading Arrangement
+Added: Duration of Trading Arrangement
+Added: Aggregate Number of Securities
+Added: Sarah Gheuens, M.D., Ph.D.
+Added: ( Chief Medical Officer, Head of Research & Development )
+Added: Adoption ( May 1, 2026 )
+Added: Rule 10b5-1 trading arrangement
+Added: Through and including August 2, 2027
+Added: Up to 151,653 shares
+Added: Cecilia Jones ( Chief Financial Officer )
+Added: Adoption ( May 1, 2026 )
+Added: Rule 10b5-1 trading arrangement
+Added: Through and including August 2, 2027
+Added: Up to 34,076 shares
+Added: Tsveta Milanova ( Chief Commercial Officer )
+Added: Adoption ( May 1, 2026 )
+Added: Rule 10b5-1 trading arrangement
+Added: Through and including July 30, 2027
+Added: Up to 9,403 shares
Incorporated by Reference
4 unchanged sentences
8-K 001-36014 March 3, 2023 3.1
−Removed: 10.1 Amended and Restated Insider Trading Policy
+Added: 10.1 Agios Pharmaceuticals, Inc.
+Added: 2023 Stock Incenti ve Plan, as amended
+Added: S-8 333-296899 June 18, 2026 99.1
31.1 Certification of principal executive officer pursuant to Rule 13a 14(a)/15d - 14(a) of the Securities Exchange Act of 1934, as amended.
15 unchanged sentences
AGIOS PHARMACEUTICALS, INC.
−Removed: April 29, 2026 By:
+Added: July 30, 2026 By:
/s/ Brian Goff
1 unchanged sentence
(principal executive officer)
−Removed: April 29, 2026 By:
+Added: July 30, 2026 By:
/s/ Cecilia Jones
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.